Glaukos Corp
Business Description
Glaukos Corporation is a medical technology company that focuses on developing and commercializing products and procedures to treat glaucoma, one of the leading causes of blindness worldwide. It was founded in 1998 and is headquartered in San Clemente, California, United States.
Glaukos Corporation offers a broad range of innovative glaucoma treatments that are designed to offer safe, long-lasting, and effective relief to patients suffering from this debilitating eye disease. The company*s flagship product is the iStent, which is the world*s first micro-bypass stent approved for use in patients with mild to moderate open-angle glaucoma. This tiny stent is placed into the eye during a minimally invasive procedure, through which it helps to alleviate intraocular pressure by improving the drainage of fluid from the eye.
Beyond the iStent, Glaukos offers a suite of glaucoma products that leverage the company*s expertise in micro-scale devices and implantable technologies. These products include the iStent Inject, a next-generation version of the iStent that offers increased flow through two stents, as well as the iStent SA, which is designed for use in patients who are undergoing cataract surgery.
In addition to its product offerings, Glaukos has a robust research and development program that is focused on advancing the field of glaucoma treatment. This includes a pipeline of novel devices, surgical systems, and drug-delivery technologies that aim to address unmet needs in the glaucoma market.
The company*s strong growth in recent years has been driven by its ability to provide compelling solutions to a significant unmet need in the ophthalmology marketplace. In 2020, Glaukos generated revenues of $196 million, a7% increase from the previous year.
Overall, Glaukos Corporation is a leading player in the ophthalmology space, with a strong track record of innovation and a commitment to improving patients* lives. As the company continues to invest in research and development, it is well-positioned to remain a key player in the glaucoma market for years to come.
|